Dedi Gilad, CEO, TytoCare

Alon Ben-Noon, Co-founder and CEO, NeuroSense Therapeutics.

Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022* Since the interview, NeuroSense successfully concluded  additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by the end of 2022 and present Top Line results by Q2 2023. The company is traded on Nasdaq under the ticker NRSN. Summary of  interview: 01:13Tell us about your career journey and meeting Shay Rishoni 06:25Tell us about ALS and why it has become a relatively well-known orphan indication 09:30 Tell us about PrimceC 12:40 Could you talk about your financing journey 16:13Did the crowdfunding process affect your public offering in some sort of way? 18:54 Is it true that zebrafish have over 70% genetic similarity to humans? How is that even possible? 21:00Could you expand on the leadership team at NeuroSense? 23:10How has your personal life changed since the company was floated to NASDAQ? 25:00You have a very unique organizational culture in NeuroSense Therapeutics and you're growing.  How do you intend to keep some of that culture while you grow? 27:30What’s next forNeuroSense? What are the next milestones and pipeline products? 30:15How long do you expect you are away from the market with the PrimeC? 31:05 Have you put any thoughts to having a companion diagnostic? 32:25What are your thoughts about the Israeli ecosystem? 34:25If you could go back to your 16-year-old self and tell yourself something, what do you think it would be? 35:40Are there any  people in your journey that were meaningful to you personally and to NeuroSense Therapeutics

Dedi Gilad, CEO, TytoCare

Dedi Gilad is the CEO of TytoCare, the healthcare industry’s first all-in-one modular telehealth device and AI-powered platform for on-demand remote medical exams and visits. To date, TytoCare has raised more than $160M in funding.

Cecile Bililious, Head of Impact and Sustainability, Pitango VC

In this episode, we're speaking with Cecile Blilious, who is the head of impact and sustainability at Pitango Venture Capital. Interview questions 00:56Tell us about your professional journey and what brought you to where you are today? 03:03 How would you define impact investments? And what does it take to be an impact investor or entrepreneur today? 07:40 Why should I as a CEO of a startup company be focused on ESG? 15:02 What are the sustainability models that you're developing at Pitango and how is this relevant to HealthTech companies? 21:54 Is there an expectation that companies will have an Impact and Sustainability Officer? 24:13 Is there going to be a personalization of expectation around ESG for health tech, specifically? 32:43Could you tell us a little bit about GITA, the Global Impact Tech Alliance, which you founded? 38:29 Is there anything that, in the next 5 years or in 5 years, you are dreaming of doing once you've put in motion this train of ESG connected to impact?

Daniella Gilboa, CEO AIVF

Today we're speaking to Daniella Gilboa, CEO of AIVF. A company that is out to transform the fertility and IVF treatment journey. Daniella was an embryologist for more than 15 years before establishing AIVF. And she's a biostatistician too. 00:55 We'd like to hear about your personal journey. What is the process that leads an embryologist to establish an AI driven IVF company? 07:42 You have said that you believe that being an embryologist is probably one of the most noble professions in the world. What did you mean by that? 09:12 What made you feel like you have the tools to take this endeavor forward as its CEO? 11:47 What in your eyes are the problems in the current status of IVF and the journey in which women are trying to or families are trying to conceive? 19:15 What would be the role of the embryologist going forward, once you have this technology out in the market? 22:45 How do you bring patients into the equation of IVF transformation? 31:51 How does the AIVF solution work? 35:02 Can you tell us where you are in the AIVF journey in terms of the product and regulation and market? 38:16 How is Dan Ariely involved with the company and what does her behavioral economics have to do with IVF? 43:36 Is there an element of the product right now that connects to the patients? Will the patient be able to follow what is happening with their embryo, remotely, while everything's happening. 47:46 Why aren't there more female CEOs in healthtech? 50:55 What is your best tip for a scientist who is thinking about opening a startup?

Yotam Drechsler & Yaron Segal PhD, BrainQ

In this episode we are talking to Yotam Drechsler and Dr. Yaron Segal from BrainQ. Yotam is the CEO of the company and Yaron is the investor, founder and Chief Innovation Officer. This is the story of a personal quest to help a loved one that morphed into a game-changing solution making a significant impact on the neurorecovery of stroke victims. BrainQ’s investigational cloud-based technology aims to reduce disability and promote neurorecovery for stroke victims. Using a Brain Computer Interface-based approach, the company’s frequency-tuned low intensity electromagnetic field therapy is designed to operate based on biological insights retrieved from brainwaves using explanatory machine learning tools. These insights are aimed at imitating the natural processes of neural network synchronization and promoting recovery processes. The system is designed to allow for scalable and decentralized care via a portable, non-invasive wearable device that is cloud-connected with integrated telemedicine tools that enable remotely monitored sessions through an app.